ObesityNCT07368855
GLP-1 Medicines and Mental Health Changes
A study testing GLP-1 in people with Obesity and Depression, run by University of California, San Diego at 1 site in United States.
Trial summary
Key question: Is the use of GLP-1 weight loss medicines - semaglutide and tirzepatide - associated with improvements in mental health and health-related quality of life? Key finding: Across six- months of GLP-1 treatment, participants reported statistically significant improvements in mental health, eating disorder… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Obesity, Depression, GLP-1
- What is being tested?
- GLP-1
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 1 siteUnited States
- Study dates
- 1 May 2024to 1 Jul 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Veterans receiving care at the VA San Diego Healthcare System
Who cannot join
- VASDHS Veterans not receiving GLP-1 medicines for obesity through the weight control clinic
Trial locations and contacts
1 site in 1 country.
United States1 site
VA San Diego Healthcare System
San Diego, California, 92161
About this study
Official title: Changes in Psychiatric Symptoms, Eating Disorder Behaviors, and Health Behaviors Following Six Months of GLP-1 Treatment for Obesity
Key question: Is the use of GLP-1 weight loss medicines - semaglutide and tirzepatide - associated with improvements in mental health and health-related quality of life?
Key finding: Across six- months of GLP-1 treatment, participants reported statistically significant improvements in mental health, eating disorder symptoms, and health-related quality of life domains such as pain interference and sleep quality.
Message for readers: Although GLP-1 medicines are prescribed primarily for weight loss and metabolic health benefits, growing evidence suggests that these medicines may also facilitate meaningful improvements in mental health and quality of life.
Read the detailed description
In a sample of veterans with obesity and established metabolic disease receiving supervised GLP-1 treatment for weight loss, we observed a consistent pattern of improved psychiatric health, eating disorder behaviors, and health-related quality of life. In addition to observing statistically significant changes across all the latter dimensions using validated psychometric measures, effect size magnitudes were also large enough to suggest potentially clinically meaningful improvements. Importantly, we observed robust evidence of decreases in depressive symptoms - averaging 30% declines in symptom severity - with no signs of increased suicidal ideation symptoms in the sample. The smaller size of this sample necessarily warrants additional research to validate these findings across the broader veteran population and among non-veteran samples.
- Conditions
- Obesity, Depression, GLP-1
- Being tested
- GLP-1
- Keywords
- Veterans, obesity, GLP-1, depression, mental health
- Medical subject headings
- Obesity, Depression, Psychological Well-Being
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GLP-1Drug
Wegovy or Zepbound
| Study group | Role | What they receive |
|---|---|---|
| GLP-1 medicine | Other | GLP-1 treatment Receives: Drug: GLP-1 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Beck Depression Inventory-2
Changes in BDI-2 scores
Measured: Six months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2026
- Study start1 May 2024
- Primary completion1 Jul 2025
- Study completion1 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by University of California, San DiegoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This study consisted of a retrospective observational study of participants receiving GLP-1 medicines for the treatment of obesity. We compared participants to their own baseline (i.e., status at the beginning of their GLP-1 treatment) to evaluate changes in psychiatric and eating disorder symptoms and health-related quality of life after six months of treatment. Participants consisted of US military veterans receiving care from a specialized weight management program in a large Veterans Affairs (VA) hospital in San Diego, California. To be eligible for GLP-1 treatment through the clinic, all veterans had previously completed lifestyle modification education and met national VA pharmacy criteria for having a diagnosis of obesity with one or more weight-related metabolic health conditions.
- Masking
- None (open label)
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, San Diego
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Thomas Rutledge, University of California, San Diego
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07368855
- Sponsor's protocol ID
- E250185
- Status last verified
- Jan 2026
- First submitted
- 20 Jan 2026
- Last updated
- 27 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data belong to VA San Diego and are not mine to share.
Study at a glance
From the registry record, last updated by the sponsor on 27 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Changes in Psychiatric Symptoms, Eating Disorder Behaviors, and Health Behaviors Following Six Months of GLP-1 Treatment for Obesity
- ClinicalTrials.gov ID
- NCT07368855
- Acronym / sponsor ID
- E250185
- Conditions
- Obesity, Depression, GLP-1
- Keywords
- Veterans, obesity, GLP-1, depression, mental health
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- University of California, San DiegoUniversity, hospital or other
- Study start
- 1 May 2024 (actual)
- Primary completion
- 1 Jul 2025 (actual)
- Study completion
- 1 Jul 2025 (actual)
- First posted
- 27 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Key question: Is the use of GLP-1 weight loss medicines - semaglutide and tirzepatide - associated with improvements in mental health and health-related quality of life?
Key finding: Across six- months of GLP-1 treatment, participants reported statistically significant improvements in mental health, eating disorder symptoms, and health-related quality of life domains such as pain interference and sleep quality.
Message for readers: Although GLP-1 medicines are prescribed primarily for weight loss and metabolic health benefits, growing evidence suggests that these medicines may also facilitate meaningful improvements in mental health and quality of life.
Detailed description
In a sample of veterans with obesity and established metabolic disease receiving supervised GLP-1 treatment for weight loss, we observed a consistent pattern of improved psychiatric health, eating disorder behaviors, and health-related quality of life. In addition to observing statistically significant changes across all the latter dimensions using validated psychometric measures, effect size magnitudes were also large enough to suggest potentially clinically meaningful improvements. Importantly, we observed robust evidence of decreases in depressive symptoms - averaging 30% declines in symptom severity - with no signs of increased suicidal ideation symptoms in the sample. The smaller size of this sample necessarily warrants additional research to validate these findings across the broader veteran population and among non-veteran samples.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This study consisted of a retrospective observational study of participants receiving GLP-1 medicines for the treatment of obesity. We compared participants to their own baseline (i.e., status at the beginning of their GLP-1 treatment) to evaluate changes in psychiatric and eating disorder symptoms and health-related quality of life after six months of treatment. Participants consisted of US military veterans receiving care from a specialized weight management program in a large Veterans Affairs (VA) hospital in San Diego, California. To be eligible for GLP-1 treatment through the clinic, all veterans had previously completed lifestyle modification education and met national VA pharmacy criteria for having a diagnosis of obesity with one or more weight-related metabolic health conditions.
| Arm | Type | Receives |
|---|---|---|
| GLP-1 medicine | Other | Drug: GLP-1GLP-1 treatment |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Veterans receiving care at the VA San Diego Healthcare System
Key exclusion criteria (1 listed)
- VASDHS Veterans not receiving GLP-1 medicines for obesity through the weight control clinic
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GLP-1Wegovy or Zepbound | Drug | GLP-1 medicine |
Primary outcome
Beck Depression Inventory-2
Time frame: Six months
Changes in BDI-2 scores
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jan 2026.
- Individual participant dataSharing planned: No. Data belong to VA San Diego and are not mine to share.
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing GLP-1 in people with Obesity and Depression, run by University of California, San Diego at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Beck Depression Inventory-2 (time frame: Six months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jan 2026.